Cindy and All,
First, Cindy you are to be commended for your unwavering support of this Co. I saw a post on another thread about MLSC and thought I would take a look.
Please understand that I am not currenly a holder. Also understand that my interest is to understand more about this Co. and not to simply be critical.
Having said that here are my initial observations after about a very short amount of research.
1. There are 100,000,000 shares authorized.(In my mind a huge amount) Currently 22,000,000 outstanding.
2. Company has been in existance, or at least public, since Nov.1991(please correct me if this is not true)
3.Clinical revenues have only been $108,000 since 1991 and none in the last two years.
4.General and administrative costs have been 4x that of research and development since the companies inception and remain that currently.(In my mind a terribly disproportionate figure, but I would need an R&D person to tell me what a proper ratio would be.
5. On 7/30/97 a Michael Franzese bought or sold (I'm not sure which)162,000 shares. (who is he?)
6. On 9/8/97 the C0.'s ERP apparently sold 148,000 shares. (Why?)
7. Today 10/16/97 20,000 shares traded but on only 2 ticks. Both apparently were buys at .32 but the stock closed down .04. @ .28.I don't quite understand that. And I could be wrong.
Cindy, I have a lot of questions about this company and my main question is about their committment to research and development vs. the salaries they are paying to their officers. I realize that competant people are important, especially in a startup company. But I need to be convinced that they are committed to product development and right now I'm not.
Just thought I would share some of my thoughts with you and the others . I welcome your response, critique, what have you.
Not much action here lately. I hope some of you are still around.
Regards,
HG |
